Program
Aspirin
Also written as “dabigatran with ASA”, “ASA” and “Acetylsalicylic acid (Aspirin, BAY1019036)”.
Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Common Cold · Thrombosis · Peptic Ulcer, led by 28 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 211 open or running | phase 4since Dec 15, 2009 | Jul 12, 2007 | Mar 10, 2027phase 1 · NCT07652723 |
| Boehringer Ingelheim | 60 open or running | phase 4since Aug 10, 2005 | Aug 10, 2005 | none ahead |
| Bristol-Myers Squibb | 50 open or running | phase 1since Jul 8, 2009 | Jul 8, 2009 | none ahead |
| Abbott | 30 open or running | phase 3since Feb 21, 2008 | Feb 21, 2008 | none ahead |
| Boston Scientific | 30 open or running | phase 4since May 1, 2012 | Dec 21, 2011 | none ahead |
| Johnson & Johnson | 30 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | none ahead |
| Aralez Pharmaceuticals | 20 open or running | phase 1since Feb 27, 2007 | Feb 27, 2007 | none ahead |
| Astellas Pharma | 20 open or running | phase 4since May 26, 2016 | Aug 1, 2011 | none ahead |
| Biogen | 20 open or running | phase 4since Mar 14, 2014 | Jan 20, 2011 | none ahead |
| Chong Kun Dang Pharmaceutical | 20 open or running | phase 1since Dec 20, 2010 | Dec 20, 2010 | none ahead |
| GlaxoSmithKline | 20 open or running | phase 1since May 2, 2013 | May 2, 2013 | none ahead |
| Merck | 20 open or running | phase 1since Nov 10, 2009 | Nov 10, 2009 | none ahead |
| PLx Pharma | 20 open or running | phase 2since Mar 10, 2009 | Mar 10, 2009 | none ahead |
| Azidus Brasil | 10 open or running | phase 3since Nov 12, 2009 | Nov 12, 2009 | none ahead |
| celonova-biosciences-inc | 10 open or running | no phasesince Aug 19, 2014 | Aug 19, 2014 | none ahead |
| Cordis | 10 open or running | phase 4since Aug 6, 2009 | Aug 6, 2009 | none ahead |
| Egymedicalpedia | 11 open or running | no phasesince Feb 7, 2024 | Feb 7, 2024 | none ahead |
| fertility-center-of-las-vegas | 11 open or running | phase 4since Nov 10, 2023 | Nov 10, 2023 | none ahead |
| GC Biopharma | 10 open or running | phase 4since May 16, 2019 | May 16, 2019 | none ahead |
| Hamad Medical | 10 open or running | phase 4since Mar 23, 2020 | Mar 23, 2020 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 10 open or running | phase 1since Feb 24, 2026 | Feb 24, 2026 | none ahead |
| new-haven-pharmaceuticals-inc | 10 open or running | phase 1since Feb 11, 2015 | Feb 11, 2015 | none ahead |
| Novartis | 10 open or running | phase 4since Nov 23, 2010 | Nov 23, 2010 | none ahead |
| Otsuka | 10 open or running | phase 1since Sep 15, 2015 | Sep 15, 2015 | none ahead |
| Regeneron Pharmaceuticals | 10 open or running | no phasesince Sep 15, 2022 | Sep 15, 2022 | none ahead |
| rhoshan-pharmaceuticals-inc | 10 open or running | phase 1since Dec 18, 2025 | Dec 18, 2025 | none ahead |
| vectura-inc | 10 open or running | phase 1since Nov 1, 2022 | Nov 1, 2022 | none ahead |
| vita-green-health-products-co-ltd | 10 open or running | phase 1since Mar 4, 2021 | Mar 4, 2021 | none ahead |
Also a collaborator on its studies: cardialysis-b-v, Terumo and clinlogix-llc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Aug 6, 2009.
- Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
- May 16, 2019GC Biopharma's first study: phase 4 study in Mucocutaneous Lymph Node SyndromeNew to GC BiopharmaGC Biopharma · NCT04003844 · 45 enrolled · Korea, Republic of
- Jul 2, 2019Phase 1 study in BioequivalencePLx Pharma · NCT04008979 · 32 enrolled
- Aug 21, 2019No phase study in Heart FailureAbbott · NCT04069156 · 628 enrolled · United States, Australia, Austria and more
- Mar 23, 2020Hamad Medical's first study: phase 4 study in Ischemic StrokeNew to Hamad MedicalHamad Medical · NCT04330872 · 42 enrolled · Qatar
- Mar 4, 2021vita-green-health-products-co-ltd's first study: phase 1 study in Cardiovascular DiseasesNew to vita-green-health-products-co-ltdvita-green-health-products-co-ltd · NCT04792723 · 24 enrolled
- Sep 15, 2022Regeneron Pharmaceuticals's first study: no phase study in DiseaseNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT05546957 · 60 enrolled · United Kingdom
- Nov 1, 2022vectura-inc's first study: phase 1 study in Respiratory AspirationNew to vectura-incvectura-inc · NCT05625334 · 86 enrolled · United States
- Nov 10, 2023fertility-center-of-las-vegas's first study: phase 4 study in Infertility, FemaleNew to fertility-center-of-las-vegasfertility-center-of-las-vegas · NCT06133803 · 130 planned · United States
- Feb 7, 2024Egymedicalpedia's first study: no phase study in Pre-EclampsiaNew to EgymedicalpediaEgymedicalpedia · NCT06261203 · 250 planned · Egypt
- Oct 22, 2024Phase 1 study in BioequivalenceBayer · NCT06655194 · 38 enrolled · Mexico
- Dec 18, 2025rhoshan-pharmaceuticals-inc's first study: phase 1 study in HealthyNew to rhoshan-pharmaceuticals-incrhoshan-pharmaceuticals-inc · NCT07323680 · 40 enrolled · Czechia
- Feb 24, 2026Laboratorios Silanes S.A. de C.V.'s first study: phase 1 study in HealthyNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT07444164 · 24 enrolled · Mexico
- Jun 8, 2026Phase 1 study in Drug-drug InteractionBayer · NCT07652723 · 16 planned · United States
Ahead
- Mar 10, 2027Primary completion: phase 1 study in Drug-drug InteractionBayer · NCT07652723
TargetBeta
“Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
The newest 60 of 70 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07652723Drug-drug Interaction · United States | 1 | Recruiting | Bayer | Mar 10, 2027 | 16 |
| NCT07444164Healthy · Mexico | 1 | Completed | Laboratorios Silanes S.A. de C.V. | Jan 23, 2025 | 24 |
| NCT07323680Healthy · Czechia | 1 | Completed | rhoshan-pharmaceuticals-inc | Jul 7, 2025 | 40 |
| NCT06655194Bioequivalence · Mexico | 1 | Completed | Bayer | Apr 6, 2025 | 38 |
| NCT06261203Pre-Eclampsia · Egypt | – | Recruiting | Egymedicalpedia | Jul 1, 2025 | 250 |
| NCT06133803Infertility, Female · United States | 4 | Recruiting | fertility-center-of-las-vegas | Dec 15, 2024 | 130 |
| NCT05625334Respiratory Aspiration · United States | 1 | Completed | vectura-inc | Mar 9, 2023 | 86 |
| NCT05546957Disease · United Kingdom | – | Completed | Regeneron Pharmaceuticals | Apr 6, 2023 | 60 |
| NCT04792723Cardiovascular Diseases | 1 | UNKNOWN | vita-green-health-products-co-ltd | Jul 1, 2021 | 24 |
| NCT04330872Ischemic Stroke · Qatar | 4 | Completed | Hamad Medical | Jan 4, 2020 | 42 |
| NCT04069156Heart Failure · United States, Australia, Austria and more | – | Completed | Abbott | Aug 10, 2023 | 628 |
| NCT04008979Bioequivalence | 1 | Completed | PLx Pharma | Jun 10, 2008 | 32 |
| NCT04003844Mucocutaneous Lymph Node Syndrome · Korea, Republic of | 4 | Completed | GC Biopharma | Nov 22, 2019 | 45 |
| NCT03698513Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2019 | 113 |
| NCT03225352Moderate Pain · United Kingdom | 1 | Completed | Bayer | Oct 7, 2017 | 12 |
| NCT03197779Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Feb 2, 2016 | 691 |
| NCT03056703Pain · United States | 1 | Completed | Bayer | Mar 2014 | 38 |
| NCT02846532Thrombosis · United States, Argentina, Belgium and more | 3 | Completed | Johnson & Johnson | Jul 16, 2020 | 112 |
| NCT02786979Diabetes Mellitus, Type 2 · China | 4 | Terminated | Astellas Pharma | Jan 2013 | 190 |
| NCT02554721Healthy · Germany | 1 | Completed | Otsuka | Mar 30, 2018 | 77 |
| NCT02439190Thrombosis · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Mar 2016 | 42 |
| NCT02394093Pharmacology, Clinical · United States | 1 | Completed | Bayer | Mar 2015 | 30 |
| NCT02370680Cardiovascular Diseases · United States | 1 | Completed | new-haven-pharmaceuticals-inc | Jul 2015 | 41 |
| NCT02341638Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Sep 2015 | 148 |
| NCT02268773Healthy | 1 | Completed | Boehringer Ingelheim | May 2000 | 27 |
| NCT02262793Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2004 | 24 |
| NCT02224235Angina, Stable · Finland | – | Terminated | celonova-biosciences-inc | Jun 2015 | 8 |
| NCT02183688Migraine Disorders | 3 | Completed | Boehringer Ingelheim | Jan 2003 | 1,889 |
| NCT02090413Multiple Sclerosis, Relapsing-Remitting · Ireland, United Kingdom | 4 | Completed | Biogen | Feb 2015 | 241 |
| NCT01847417Ulcer · India | 1 | Completed | GlaxoSmithKline | Jul 1, 2013 | 24 |
| NCT01847404Ulcer · India | 1 | Completed | GlaxoSmithKline | Jun 28, 2013 | 24 |
| NCT01830543Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Jul 28, 2016 | 2,124 |
| NCT01776424Coronary Artery Disease · United States, Argentina, Australia and more | 3 | Completed | Bayer | Jul 21, 2017 | 27,395 |
| NCT01589978Coronary Artery Disease · United States | 4 | Completed | Boston Scientific | Aug 2014 | 2,681 |
| NCT01552798Headache · United States | 3 | Terminated | Bayer | Jun 4, 2012 | 9 |
| NCT01500434Coronary Artery Disease · United States, Australia, Belgium and more | 3 | Completed | Boston Scientific | Mar 2011 | 102 |
| NCT01510327Coronary Artery Disease · United States, Japan | 3 | Completed | Boston Scientific | Feb 2010 | 22 |
| NCT01496261Coronary Artery Disease · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Sep 2011 | 60 |
| NCT01424332Pharmacodynamic and Pharmacokinetic Interaction · France | 1 | Completed | Astellas Pharma | Mar 2008 | 24 |
| NCT01420094Toothache · United States | 3 | Completed | Bayer | Sep 8, 2011 | 510 |
| NCT01361399Common Cold · Russian Federation, Ukraine | 3 | Completed | Bayer | May 28, 2005 | 1,088 |
| NCT01465009Common Cold · United Kingdom | 4 | Completed | Bayer | 508 | |
| NCT01464983Headache · United Kingdom | 4 | Completed | Bayer | 1,115 | |
| NCT01464944Respiratory Tract Infections · Russian Federation, Ukraine | 4 | Completed | Bayer | 392 | |
| NCT01281111Healthy · United States | 1 | Completed | Biogen | Mar 18, 2011 | 56 |
| NCT01663038Coronary Artery Disease · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jan 2011 | 60 |
| NCT01248468Pain · United States | 4 | Completed | Novartis | Mar 2011 | 752 |
| NCT01227629Atrial Fibrillation · United States, Denmark, Sweden | 2 | Completed | Boehringer Ingelheim | Nov 2004 | 502 |
| NCT01122602Drugs, Investigational · United States | 3 | Completed | Bayer | Jul 29, 2010 | 500 |
| NCT01117636Drugs, Investigational · United States | 3 | Completed | Bayer | Jul 7, 2010 | 514 |
| NCT01108588Healthy Volunteers | 1 | Completed | Merck | Aug 2010 | 15 |
| NCT01081353Pharmacokinetics · United States | 1 | Completed | Bayer | Mar 2010 | 26 |
| NCT01072604Pharmacokinetics · United States | 1 | Completed | Bayer | Aug 2009 | 30 |
| NCT01033526Common Cold · Italy | 4 | Completed | Bayer | 388 | |
| NCT01062360Common Cold · United States, Italy, Poland and more | 3 | Completed | Bayer | May 14, 2007 | 1,016 |
| NCT01028079Low Back Pain · Germany, United Kingdom | 3 | Completed | Bayer | 338 | |
| NCT01012349Treatment of Episodic Tension Headache · Brazil | 3 | UNKNOWN | Azidus Brasil | May 2011 | 152 |
| NCT01012219Hyperlipoproteinemia Type II | 1 | Completed | Merck | Mar 2010 | 36 |
| NCT00963443Common Cold · United Kingdom | 3 | Completed | Bayer | Mar 2012 | 833 |
| NCT00954707Coronary Artery Disease · United States | 4 | UNKNOWN | Cordis | Jan 2012 | 2,509 |
How it is read
Names in the registry
- “Aspirin”, 25 entries
- “dabigatran with ASA”, 6 entries
- “ASA”, 5 entries
- “Acetylsalicylic acid (Aspirin, BAY1019036)”, 5 entries
- “Acetylsalicylic acid (Aspirin, BAYE4465)”, 5 entries
Codes read as this program: BAY1019036.
Conditions, from the studies’ own filings
- Coronary Artery Disease, 9 studies
- Cardiovascular Diseases, 5 studies
- Common Cold, 5 studies
- Thrombosis, 4 studies
- Peptic Ulcer, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.